Pharmaceutical Intermediates
+- Pharmaceutical Intermediates
- > Analgesics
- > Anesthetics
- > Anti-Addiction Agents
- > Antibacterials
- > Anticonvulsants
- > Antidementia Agents
- > Antidepressants
- > Antiemetics
- > Antifungals
- > Antigout Agents
- > Anti-inflammatory Agents
- > Antimigraine Agents
- > Antineoplastics
- > Antiparasitics
- > Antiparkinson Agents
- > Antipsychotics
- > Antispasticity Agents
- > Antivirals
- > Anxiolytics
- > Blood Glucose Regulators
- > Blood Products
- > Cardiovascular Agents
- > CNS Agents
- > Dental and Oral Agents
- > Dermatological Agents
- > Electrolytes
- > Gastrointestinal Agents
- > Genetic/Enzyme Disorder
- > Genitourinary Agents
- > Immunological Agents
- > Metabolic Bone Disease
- > Ophthalmic Agents
- > Respiratory Tract
- > Skeletal Muscle Relaxants
- > Sleep Disorder Agents
- > Oled Material Intermediate
- > Heterocyclic Compound
- > Bulk Drug Intermediates
-
The 85th API China
2021-02-18 -
84th API China
2021-02-18 -
The 84th API China
2021-02-18 -
The 85th API China special report
2021-02-18 -
4 U.S. pharmaceutical R&D transactions worth watching
2021-02-01 -
CPHI South East Asia 2021
2021-01-29
Antiparasitics
Heterocyclic Compound
Immunological Agents
-
4-CHLORO-7-((2-(TRIMETHYLSILYL)ETHOXY)METHYL)-7H-PYRROLO[2,3-D]PYRIMIDINE 98%
$1-1000/G FOB
-
$10/KG FOB
-
3-bis(4-Methylbenzoyloxy)succinate) 98%
-
Benzonitrile, 3-ethoxy-4-Methoxy- 98%